drugset / Trial / NCT00409526

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526

Phase 4 Terminated 1 enrolled University of Chicago
NaSingle-groupOpen-labelTreatment

Summary

Inhaled Iloprost will be administered to near term infants with Persistent Pulmonary Hypertension of the Newborn in two different doses in order to test safety and efficacy in reducing pulmonary artery pressure.

Timeline

Start
2006-12
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Iloprost Other / unclassified 50 ug Inhaled
Subject Iloprost Other / unclassified 100 ug Inhaled